Global precision cardiology market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. The market growth can be attributed to the rising geriatric population as they are more susceptible to such ailments. In addition, the growing prevalence of cardiovascular diseases, owing to the adoption of unhealthy and sedentary lifestyles such as eating junk and processed foods, restricted physical activities, and high alcohol consumption, are creating greater need for precision cardiology.
Precision cardiology (PM) refers to an integrative approach of dealing with cardiovascular disease prevention and treatment. This approach proposes the customization of healthcare treatments, procedures, and medicines depending on the patient’s genetics, lifestyle, and other molecular or cellular analysis. Precision cardiology involves treatment tailored to a subgroup of patients with shared characteristics for improved outcomes. Besides, growing awareness regarding precision cardiology, coupled with its increased adoption by healthcare providers, is fueling the market growth. This is primarily because, precision cardiology helps healthcare providers in better understanding several things such as the patient’s environment, lifestyle, and heredity, which might positively influence the result of the treatment. Thus, healthcare providers across the globe are increasingly employing precision cardiology to accurately predict the right, safe, and most effective treatment for the patient.
Artificial Intelligence in Precision Cardiology Fuels the Market Growth
The integration of AI with precision cardiology is acting as a major growth-inducing factor for the global precision cardiology market. Machine learning algorithms are utilized to analyze and draw inferences from the huge amounts of data generated from patients and healthcare institutions. AI techniques are also used in genome sequencing and precision cardiovascular medicine to understand phenotypes and genotypes in the existing diseases and improve the quality of patient care. This signifies that the rate of hospital readmissions and mortality will reduce over the coming years leveraging, hence making the overall healthcare cost-effective for the patients.
Rising Prevalence of Cardiovascular Diseases Boost the Market Growth
The global precision technology market is witnessing a robust growth due to the rising cases of cardiovascular diseases such as diabetes, hypertension, and cardiovascular disorders such as coronary artery disease (CAD). According to a report, in 2020, nearly 697,000 people in the United States died from heart disease, that equals to one in every five deaths. As a result, the patients are increasingly inclining towards early detection and screening in order to prevent the disease from becoming fatal. In addition, the decreasing cost of sequencing is providing a positive outlook to the market. Furthermore, several leading market players are focusing on the development of precision cardiology tests based on advanced sequencing technologies to support healthcare professionals in taking informed decisions in the field of cardiovascular care. All the aforementioned factors are anticipated to propel the global precision cardiology market in the coming years.
DOWNLAOD FREE SAMPLE REPORT
Market Segmentation
In terms of country, the United States is expected to hold a significant share in the global precision cardiology market, owing to the advanced healthcare infrastructure and increasing mortality rates from cardiovascular disorders in the country.
Company Profile
Eurofins Genomics LLC, Laboratory Corporation of America Holdings, Thermos Fischer Scientific, Inc., PerkinElmer, Inc., Sema4 OpCo, Inc., Quest Diagnostics Inc., OraSure Technologies, Inc., OPKO Health, Inc., Invitae Corporation, Illumina, Inc., Fulgent Genetics, Inc., Exact Sciences Corporation, CENTOGENE N.V., Konica Minolta, Inc., and Devyser Diagnostics AB are the leading market players in the global precision cardiology market.
Attribute | Details |
Base Year | 2021 |
Historical Data | 2017 – 2020 |
Estimated Year | 2022 |
Forecast Period | 2023 – 2027 |
Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
Report coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | · Offering · Sample Type · Technology · Application · End User |
Regional scope | North America, Europe, Asia Pacific, Middle east and Africa, South America |
Key companies profiled | Eurofins Genomics LLC, Laboratory Corporation of America Holdings, Thermos Fischer Scientific, Inc., PerkinElmer, Inc., Sema4 OpCo, Inc., Quest Diagnostics Inc., OraSure Technologies, Inc., OPKO Health, Inc., Invitae Corporation, Illumina, Inc., Fulgent Genetics, Inc., Exact Sciences Corporation, CENTOGENE N.V., Konica Minolta, Inc., and Devyser Diagnostics AB |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |